Heleia Roca-Ho
Overview
Explore the profile of Heleia Roca-Ho including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
470
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Petazzi P, Gutierrez-Aguera F, Roca-Ho H, Castano J, Bueno C, Alvarez N, et al.
Front Cell Dev Biol
. 2024 Dec;
12:1484955.
PMID: 39676795
The CRISPR/Cas9 system has transformed genome editing by enabling precise modifications for diverse applications. Recent advancements, including base editing and prime editing, have expanded its utility beyond conventional gene knock-out...
2.
Lopez-Millan B, Costales P, Gutierrez-Aguera F, de la Guardia R, Roca-Ho H, Vinyoles M, et al.
Cancers (Basel)
. 2022 Mar;
14(6).
PMID: 35326743
Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Patients with AML harboring a constitutively active internal tandem duplication mutation (ITD) in the FMS-like kinase tyrosine kinase...
3.
Rodriguez-Cortez V, Navarrete-Meneses M, Molina O, Velasco-Hernandez T, Gonzalez J, Romecin P, et al.
Haematologica
. 2021 Oct;
107(2):544-549.
PMID: 34706497
No abstract available.
4.
Zanetti S, Velasco-Hernandez T, Gutierrez-Aguera F, Diaz V, Romecin P, Roca-Ho H, et al.
Mol Ther
. 2021 Sep;
30(2):550-563.
PMID: 34478871
CD19-directed chimeric antigen receptor (CAR) T cells have yielded impressive response rates in refractory/relapse B cell acute lymphoblastic leukemia (B-ALL); however, most patients ultimately relapse due to poor CAR T ...
5.
de la Guardia R, Velasco-Hernandez T, Gutierrez-Aguera F, Roca-Ho H, Molina O, Nombela-Arrieta C, et al.
Blood Adv
. 2021 Sep;
5(23):4842-4854.
PMID: 34470043
Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Disease heterogeneity is well documented, and patient stratification determines treatment decisions. Patient-derived xenografts (PDXs) from risk-stratified AML are...
6.
Velasco-Hernandez T, Zanetti S, Roca-Ho H, Gutierrez-Aguera F, Petazzi P, Sanchez-Martinez D, et al.
J Immunother Cancer
. 2020 Aug;
8(2).
PMID: 32788237
Background: There are few therapeutic options available for patients with B-cell acute lymphoblastic leukemia (B-ALL) relapsing as CD19 either after chemotherapy or CD19-targeted immunotherapies. CD22-chimeric antigen receptor (CAR) T cells...
7.
Roca-Ho H, Palau V, Gimeno J, Pascual J, Soler M, Riera M
Lab Invest
. 2020 May;
100(9):1169-1183.
PMID: 32472097
Type 1 diabetes is a T-cell mediated autoimmune disease characterized by pancreatic beta cells destruction. Angiotensin-converting enzyme 2 (ACE2), a component of renin-angiotensin system (RAS) has been identified in pancreas...
8.
Molina O, Vinyoles M, Granada I, Roca-Ho H, Gutierrez-Aguera F, Valledor L, et al.
Blood
. 2020 Apr;
136(3):313-327.
PMID: 32321174
B-cell acute lymphoblastic leukemia (ALL; B-ALL) is the most common pediatric cancer, and high hyperdiploidy (HyperD) identifies the most common subtype of pediatric B-ALL. Despite HyperD being an initiating oncogenic...
9.
Petazzi P, Torres-Ruiz R, Fidanza A, Roca-Ho H, Gutierrez-Aguera F, Castano J, et al.
Mol Ther Nucleic Acids
. 2020 Mar;
20:196-204.
PMID: 32171171
Human pluripotent stem cells (hPSCs) and mesenchymal stromal/stem cells (hMSCs) are clinically relevant sources for cellular therapies and for modeling human development and disease. Many stem cell-based applications rely on...
10.
Sanchez-Martinez D, Baroni M, Gutierrez-Aguera F, Roca-Ho H, Blanch-Lombarte O, Gonzalez-Garcia S, et al.
Blood
. 2019 Feb;
133(21):2291-2304.
PMID: 30796021
Relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) has a dismal outcome, and no effective targeted immunotherapies for T-ALL exist. The extension of chimeric antigen receptor (CAR) T cells (CARTs) to T-ALL...